European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy. Another goal is achieving a stable deep molecular response (DMR) and discontinuing medication for treatment-free remission (TFR). The European LeukemiaNet convened an expert panel to critically evaluate and update the evidence to achieve these goals since its previous recommendations. First-line treatment is a tyrosine kinase inhibitor (TKI; imatinib brand or generic, dasatinib, nilotinib, and bosutinib are available first-line). Generic imatinib is the cost-effective initial treatment in CP. Various contraindications and side-effects…

• A
  Amgen
• P
  Pfizer
• GS
  Gilead Sciences
• TP
  Teva Pharmaceutical Industries
• AP
  Ariad Pharmaceuticals
• C
  Celgene
• AP
  Astex Pharmaceuticals
• AP
  Agios Pharmaceuticals
• I
  Incyte
• AP
  Ascentage Pharma
• S
  Seagen
• D
  Daiichi-Sankyo
• AP
  Astellas Pharma
• S
  Servier
• SP
  Sun Pharma
• I
  Italfarmaco
• SF
  Scheme for Promotion of Academic and Research Collaboration
• DS
  Daiichi Sankyo Europe